World journal of oncology · 2026
Human Epidermal Growth Factor Receptor 2 Negative, Low, and Overexpression in Breast Cancer Patients: Study on Recurrence-Free and Overall Survival.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soewoto Widyanti, Yarso Kristanto Yuli, Adnyana Ida Bagus Budhi Surya, Wibisono Wibisono, Herida Alifia Ramadhani, Assakandari Arie, Maylitadara Diesta, Susanto Aldona Akhira, Nisa Azzahra Fadhlila Aulia, Steve Cornelius
Аннотация
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) expression is a key prognostic marker in breast cancer. Recently, HER2-low breast cancer has emerged as a potentially distinct subgroup; however, its prognostic significance remains controversial, particularly in real-world clinical settings. This study aimed to evaluate recurrence-free and overall survival (OS) across HER2 expression categories: HER2-negative, HER2-low, and HER2-overexpressing.
METHODS: This observational analytic study used a retrospective cohort design conducted at Dr. Moewardi Hospital, a tertiary referral center in Central Java, Indonesia. A total of 2,310 breast cancer patients with complete HER2 immunohistochemistry (IHC) results and documented survival data from 2018 to 2020 were included. HER2 status was classified as HER2-negative (IHC 0), HER2-low (IHC 1+ or IHC 2+ without amplification), and HER2-overexpression (HER2-positive). The primary outcome was OS, defined as the time from diagnosis to death from any cause. Survival was analyzed using the Kaplan-Meier method, with comparisons by log-rank test and risk estimation using Cox proportional hazards regression.
RESULTS: Of the patients, 43.6% were HER2-negative, 21.3% HER2-low, and 35.2% HER2-overexpressing. Kaplan-Meier analysis showed significant differences in OS among groups (log-rank χ2 = 17.150; P < 0.001). HER2-negative patients had the best outcomes (mean OS 6.38 years; median unreached), followed by HER2-low (mean OS 5.60 years; median 4.00 years), and HER2-overexpression (mean OS 4.80 years; median 3.00 years). Significant differences were observed between HER2-negative vs. HER2-low (P = 0.015) and HER2-negative vs. HER2-overexpression (P < 0.001), but not between HER2-low and HER2-overexpression (P = 0.356). In Cox analysis, HER2-negative status reduced mortality risk by 22.2% compared with HER2-overexpression (hazard ratio 0.778; 95% confidence interval, 0.679-0.892; P < 0.001), while HER2-low showed no significant difference (hazard ratio 0.935; P = 0.413).
CONCLUSIONS: HER2 expression is a significant prognostic factor in breast cancer. HER2-low patients have worse survival than HER2-negative patients and outcomes comparable to HER2-overexpression. These findings suggest that HER2-low breast cancer should not be considered low-risk and have important implications for prognostic stratification and treatment planning.
METHODS: This observational analytic study used a retrospective cohort design conducted at Dr. Moewardi Hospital, a tertiary referral center in Central Java, Indonesia. A total of 2,310 breast cancer patients with complete HER2 immunohistochemistry (IHC) results and documented survival data from 2018 to 2020 were included. HER2 status was classified as HER2-negative (IHC 0), HER2-low (IHC 1+ or IHC 2+ without amplification), and HER2-overexpression (HER2-positive). The primary outcome was OS, defined as the time from diagnosis to death from any cause. Survival was analyzed using the Kaplan-Meier method, with comparisons by log-rank test and risk estimation using Cox proportional hazards regression.
RESULTS: Of the patients, 43.6% were HER2-negative, 21.3% HER2-low, and 35.2% HER2-overexpressing. Kaplan-Meier analysis showed significant differences in OS among groups (log-rank χ2 = 17.150; P < 0.001). HER2-negative patients had the best outcomes (mean OS 6.38 years; median unreached), followed by HER2-low (mean OS 5.60 years; median 4.00 years), and HER2-overexpression (mean OS 4.80 years; median 3.00 years). Significant differences were observed between HER2-negative vs. HER2-low (P = 0.015) and HER2-negative vs. HER2-overexpression (P < 0.001), but not between HER2-low and HER2-overexpression (P = 0.356). In Cox analysis, HER2-negative status reduced mortality risk by 22.2% compared with HER2-overexpression (hazard ratio 0.778; 95% confidence interval, 0.679-0.892; P < 0.001), while HER2-low showed no significant difference (hazard ratio 0.935; P = 0.413).
CONCLUSIONS: HER2 expression is a significant prognostic factor in breast cancer. HER2-low patients have worse survival than HER2-negative patients and outcomes comparable to HER2-overexpression. These findings suggest that HER2-low breast cancer should not be considered low-risk and have important implications for prognostic stratification and treatment planning.